Bigdon Eileen, Steinhorst Nils Alexander, Weissleder Stephanie, Durchkiv Vasyl, Stübiger Nicole
Department of Ophthalmology, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany.
Augenzentrum Schleswig-Holstein, Peter-Ox-Straße 7, 25917 Leck, Germany.
J Clin Med. 2022 Apr 26;11(9):2419. doi: 10.3390/jcm11092419.
Background/Aims: Controversy exists regarding 3- or 4 drug antituberculosis therapy (conventional ATT) in uveitis patients having latent tuberculosis (LTB), especially while initiating therapy with corticosteroids and/or other immunosuppressants. Methods: We performed a monocentral retrospective analysis of posterior uveitis patients with latent TB. Latent TB was diagnosed, in case of a positive QuantiFERON®-TB-Gold test and normal chest imaging, after ruling out other causes of infectious and noninfectious uveitis. Patients with active TB were excluded. From 2016 to 2020 we included 17 patients. Ophthalmological evaluation consisted of Best corrected visual acuity (BCVA), slit lamp examination, fundoscopy, OCT, and fluorescein- and indocyaningreen- angiography before and at months 3, 6, 12, 24, and the last follow-up after treatment. Results: Initially, all patients had active posterior uveitis with occlusive (n = 5 patients) and nonocclusive retinal vasculitis (n = 12 patients). Mean follow up was 28 ± 15 months. Therapy was started with systemic corticosteroids (mean prednisolone equivalent 71.3 mg/d) and already after 3 months it could be tapered to a mean maintenance dosage of 8.63 mg/d. Additional immunosuppressive treatment with cs- or bDMARDs was initiated in 14 patients (82%) due to recurrences of uveitis while tapering the corticosteroids <10 mg per/day or because of severe inflammation at the initial visit. While being on immunosuppression, best corrected visual acuity increased from 0.56 logMAR to 0.32 logMAR during follow-up and only three patients had one uveitis relapse, which was followed by switch of immunosuppressive treatment. As recommended, TB prophylaxis with 300 mg/d isoniazid was administered in 11 patients for at least 9 months while being on TNF-alpha-blocking agents. No patient developed active tuberculosis during immunosuppressive therapy. Conclusion: Mainly conventional ATT is strongly recommended—as monotherapy or in combination with immunosuppressives—for effective treatment in patients with uveitis due to latent TB. Although in our patient group no conventional ATT was initiated, immunosuppression alone occurred as an efficient treatment. Nevertheless, due to possible activation of TB, isoniazid prophylaxis is mandatory in latent TB patients while being on TNF-alpha blocking agents.
背景/目的:对于患有潜伏性结核病(LTB)的葡萄膜炎患者采用三联或四联抗结核治疗(传统抗结核治疗,conventional ATT)存在争议,尤其是在开始使用皮质类固醇和/或其他免疫抑制剂治疗时。方法:我们对患有潜伏性结核的后葡萄膜炎患者进行了单中心回顾性分析。在排除感染性和非感染性葡萄膜炎的其他病因后,若QuantiFERON®-TB-Gold检测呈阳性且胸部影像学检查正常,则诊断为潜伏性结核。排除活动性结核患者。2016年至2020年,我们纳入了17例患者。眼科评估包括治疗前以及治疗后3、6、12、24个月和最后一次随访时的最佳矫正视力(BCVA)、裂隙灯检查、眼底镜检查、光学相干断层扫描(OCT)以及荧光素和吲哚菁绿血管造影。结果:最初,所有患者均患有伴有闭塞性(5例患者)和非闭塞性视网膜血管炎(12例患者)的活动性后葡萄膜炎。平均随访时间为28±15个月。治疗从全身使用皮质类固醇开始(平均泼尼松等效剂量71.3mg/d),3个月后即可减至平均维持剂量8.63mg/d。由于在将皮质类固醇减至<10mg/天时葡萄膜炎复发或因初诊时炎症严重,14例患者(82%)开始额外使用环孢素或生物制剂改善病情的抗风湿药(cs-或bDMARDs)进行免疫抑制治疗。在接受免疫抑制治疗期间,随访期间最佳矫正视力从0.56 logMAR提高到0.32 logMAR,只有3例患者发生了一次葡萄膜炎复发,随后更换了免疫抑制治疗方案。按照建议,11例患者在使用肿瘤坏死因子-α阻滞剂期间接受了300mg/d异烟肼的结核预防治疗,疗程至少9个月。在免疫抑制治疗期间,没有患者发生活动性结核病。结论:强烈推荐主要采用传统抗结核治疗——无论是单一疗法还是与免疫抑制剂联合使用——用于有效治疗因潜伏性结核导致的葡萄膜炎患者。虽然在我们的患者组中没有开始传统抗结核治疗,但单独使用免疫抑制治疗也是一种有效的治疗方法。然而,由于可能激活结核,潜伏性结核患者在使用肿瘤坏死因子-α阻滞剂时必须进行异烟肼预防治疗。